/ Pfizer
/ Best Stocks, Market Analysis
Santa Claus Rally: 3 Discounted Stocks Heading into 2026
Pfizer’s comeback, Newmont’s resilience, and Utz’s growth positioning make them compelling candidates for year-end gains.
November 12, 2025
Pfizer Shares Gain Amid Reports of Deal with the US Government
Pfizer stock climbed over 3% on news of an impending drug-pricing deal with the Trump administration.
September 30, 2025
MTSR Shares Jump After Pfizer Merger Agreement
Metsera stock skyrocketed 62% as Pfizer struck a $4.9 billion acquisition agreement focused on obesity therapies.
September 22, 2025
3 Value Stocks Worth Buying in Current Market Conditions
Big Pharma, Big Tech and REIT is on the value menu. Discount opportunities at this level are rare.
April 01, 2025
Pfizer Targets Up to $64B Revenue in 2025 Amid Strategic Cost Savings
Pfizer projects 2025 revenues between $61 billion and $64 billion, with a focus on cost savings and strategic initiatives to drive growth.
December 17, 2024More from The Tokenist / Pfizer
Top 3 Discounted Value Stocks Worth Buying Now
September 30, 2024
3 Defensive Stocks to Protect Your Portfolio in 2024
April 23, 2024
Three Safe Dividend Paying Stocks With High Yields to Hold in 2024
December 20, 2023
Back to 
